Literature DB >> 26292978

Parainflammation, chronic inflammation, and age-related macular degeneration.

Mei Chen1, Heping Xu2.   

Abstract

Inflammation is an adaptive response of the immune system to noxious insults to maintain homeostasis and restore functionality. The retina is considered an immune-privileged tissue as a result of its unique anatomic and physiologic properties. During aging, the retina suffers from a low-grade chronic oxidative insult, which sustains for decades and increases in level with advancing age. As a result, the retinal innate-immune system, particularly microglia and the complement system, undergoes low levels of activation (parainflammation). In many cases, this parainflammatory response can maintain homeostasis in the healthy aging eye. However, in patients with age-related macular degeneration, this parainflammatory response becomes dysregulated and contributes to macular damage. Factors contributing to the dysregulation of age-related retinal parainflammation include genetic predisposition, environmental risk factors, and old age. Dysregulated parainflammation (chronic inflammation) in age-related macular degeneration damages the blood retina barrier, resulting in the breach of retinal-immune privilege, leading to the development of retinal lesions. This review discusses the basic principles of retinal innate-immune responses to endogenous chronic insults in normal aging and in age-related macular degeneration and explores the difference between beneficial parainflammation and the detrimental chronic inflammation in the context of age-related macular degeneration. © Society for Leukocyte Biology.

Entities:  

Keywords:  blood-retina barrier; complement; immune privilege; microglia; retina

Mesh:

Year:  2015        PMID: 26292978      PMCID: PMC4733662          DOI: 10.1189/jlb.3RI0615-239R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  179 in total

1.  Dendritic cells are early responders to retinal injury.

Authors:  Ute Lehmann; Neal D Heuss; Scott W McPherson; Heidi Roehrich; Dale S Gregerson
Journal:  Neurobiol Dis       Date:  2010-05-23       Impact factor: 5.996

2.  Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins.

Authors:  J H Sohn; H J Kaplan; H J Suk; P S Bora; N S Bora
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-10       Impact factor: 4.799

Review 3.  Understanding age-related macular degeneration (AMD): relationships between the photoreceptor/retinal pigment epithelium/Bruch's membrane/choriocapillaris complex.

Authors:  Imran Bhutto; Gerard Lutty
Journal:  Mol Aspects Med       Date:  2012-04-21

4.  Elevated Plasma Pentraxin3 Levels and Its Association with Neovascular Age-related Macular Degeneration.

Authors:  Jung Kee Min; Jaehong Kim; Je Moon Woo
Journal:  Ocul Immunol Inflamm       Date:  2014-03-21       Impact factor: 3.070

Review 5.  Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases.

Authors:  Claudio Franceschi; Judith Campisi
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-06       Impact factor: 6.053

Review 6.  S100B in neuropathologic states: the CRP of the brain?

Authors:  Jon Sen; Antonio Belli
Journal:  J Neurosci Res       Date:  2007-05-15       Impact factor: 4.164

7.  Complement gene expression and regulation in mouse retina and retinal pigment epithelium/choroid.

Authors:  Chang Luo; Mei Chen; Heping Xu
Journal:  Mol Vis       Date:  2011-06-14       Impact factor: 2.367

8.  Insulin-like growth factor binding proteins 4 and 7 released by senescent cells promote premature senescence in mesenchymal stem cells.

Authors:  V Severino; N Alessio; A Farina; A Sandomenico; M Cipollaro; G Peluso; U Galderisi; A Chambery
Journal:  Cell Death Dis       Date:  2013-11-07       Impact factor: 8.469

9.  Lysosomal-mediated waste clearance in retinal pigment epithelial cells is regulated by CRYBA1/βA3/A1-crystallin via V-ATPase-MTORC1 signaling.

Authors:  Mallika Valapala; Christine Wilson; Stacey Hose; Imran A Bhutto; Rhonda Grebe; Aling Dong; Seth Greenbaum; Limin Gu; Samhita Sengupta; Marisol Cano; Sean Hackett; Guotong Xu; Gerard A Lutty; Lijin Dong; Yuri Sergeev; James T Handa; Peter Campochiaro; Eric Wawrousek; J Samuel Zigler; Debasish Sinha
Journal:  Autophagy       Date:  2014-01-23       Impact factor: 16.016

10.  Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

Authors:  Usha Chakravarthy; Simon P Harding; Chris A Rogers; Susan M Downes; Andrew J Lotery; Sarah Wordsworth; Barnaby C Reeves
Journal:  Ophthalmology       Date:  2012-05-11       Impact factor: 12.079

View more
  107 in total

1.  4-Hydroxy-7-oxo-5-heptenoic Acid Lactone Is a Potent Inducer of the Complement Pathway in Human Retinal Pigmented Epithelial Cells.

Authors:  Mikhail Linetsky; Karina S Bondelid; Sofiya Losovskiy; Vadym Gabyak; Mario J Rullo; Thomas I Stiadle; Vasu Munjapara; Priyali Saxena; Duoming Ma; Yu-Shiuan Cheng; Andrew M Howes; Emeka Udeigwe; Robert G Salomon
Journal:  Chem Res Toxicol       Date:  2018-07-09       Impact factor: 3.739

Review 2.  Age-related macular degeneration.

Authors:  Monika Fleckenstein; Tiarnán D L Keenan; Robyn H Guymer; Usha Chakravarthy; Steffen Schmitz-Valckenberg; Caroline C Klaver; Wai T Wong; Emily Y Chew
Journal:  Nat Rev Dis Primers       Date:  2021-05-06       Impact factor: 52.329

3.  Assessment of three successive treatments of ranibizumab on neovascular macular degeneration by OCT angiography.

Authors:  Juming Zhu; Qing Peng; Tu Su; Minli Wang; Fang Wang
Journal:  Exp Ther Med       Date:  2020-11-19       Impact factor: 2.447

4.  A novel murine model for contact lens wear reveals clandestine IL-1R dependent corneal parainflammation and susceptibility to microbial keratitis upon inoculation with Pseudomonas aeruginosa.

Authors:  Matteo M E Metruccio; Stephanie J Wan; Hart Horneman; Abby R Kroken; Aaron B Sullivan; Tan N Truong; James J Mun; Connie K P Tam; Robin Frith; Laurence Welsh; Melanie D George; Carol A Morris; David J Evans; Suzanne M J Fleiszig
Journal:  Ocul Surf       Date:  2018-11-12       Impact factor: 5.033

5.  Microglia in the primate macula: specializations in microglial distribution and morphology with retinal position and with aging.

Authors:  Janani Singaravelu; Lian Zhao; Robert N Fariss; T Michael Nork; Wai T Wong
Journal:  Brain Struct Funct       Date:  2017-02-17       Impact factor: 3.270

Review 6.  Neutrophil-to-lymphocyte ratio in ocular diseases: a systematic review.

Authors:  Bengi Ece Kurtul; Pinar Altiaylik Ozer
Journal:  Int J Ophthalmol       Date:  2019-12-18       Impact factor: 1.779

Review 7.  New insight into the role of the complement in the most common types of retinopathy-current literature review.

Authors:  Martyna Chrzanowska; Anna Modrzejewska; Monika Modrzejewska
Journal:  Int J Ophthalmol       Date:  2018-11-18       Impact factor: 1.779

8.  Lipofuscin-dependent stimulation of microglial cells.

Authors:  Martin Dominik Leclaire; Gerburg Nettels-Hackert; Jeannette König; Annika Höhn; Tilman Grune; Constantin E Uhlig; Uwe Hansen; Nicole Eter; Peter Heiduschka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-01-28       Impact factor: 3.117

9.  Oxidative damage induces MCP-1 secretion and macrophage aggregation in age-related macular degeneration (AMD).

Authors:  Zhaojiang Du; Xuemei Wu; Meixia Song; Peng Li; Li Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-11-04       Impact factor: 3.117

10.  miR-30a-5p inhibition promotes interaction of Fas+ endothelial cells and FasL+ microglia to decrease pathological neovascularization and promote physiological angiogenesis.

Authors:  Salome Murinello; Yoshihiko Usui; Susumu Sakimoto; Maki Kitano; Edith Aguilar; H Maura Friedlander; Amelia Schricker; Carli Wittgrove; Yoshihiro Wakabayashi; Michael I Dorrell; Peter D Westenskow; Martin Friedlander
Journal:  Glia       Date:  2018-11-28       Impact factor: 7.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.